Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | EBMT 2020: cellular therapy day

Annalisa Ruggeri • 31 Aug 2020
EBMT 2020
CAR-T

Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses cellular therapy, specifically the engineering of T-cells and the use of mesenchymal stem cells (MSCs) for treating graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Annalisa Ruggeri

Register for the hybrid EBMT-EHA 8th European CAR T-cell meeting: a message from the chair
1:48
Register for the hybrid EBMT-EHA 8th European CAR T-cell meeting: a message from the chair
Annalisa Ruggeri • 5 Feb 2026
Graft failure after unmanipulated haplo-HSCT with PT-Cy in AML
10:00
Graft failure after unmanipulated haplo-HSCT with PT-Cy in AML
Annalisa Ruggeri • 26 Aug 2020
HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
3:39
HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri • 7 Dec 2019
Association of HLA matching with outcome of UD-HSCT: EBMT study
2:00
Association of HLA matching with outcome of UD-HSCT: EBMT study
Annalisa Ruggeri • 7 Dec 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals